S

Sana Biotechnology Inc
NASDAQ:SANA

Watchlist Manager
Sana Biotechnology Inc
NASDAQ:SANA
Watchlist
Price: 2.61 USD 11.06% Market Closed
Market Cap: 580.6m USD
Have any thoughts about
Sana Biotechnology Inc?
Write Note

Sana Biotechnology Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sana Biotechnology Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
S
Sana Biotechnology Inc
NASDAQ:SANA
Net Income (Common)
-$283.3m
CAGR 3-Years
0%
CAGR 5-Years
-84%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Sana Biotechnology Inc
Glance View

Market Cap
582.3m USD
Industry
Biotechnology

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 383 full-time employees. The company went IPO on 2021-02-04. The firm is focused on creating and delivering engineered cells as medicines for patients. The firm develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

SANA Intrinsic Value
0.92 USD
Overvaluation 65%
Intrinsic Value
Price
S

See Also

What is Sana Biotechnology Inc's Net Income (Common)?
Net Income (Common)
-283.3m USD

Based on the financial report for Dec 31, 2023, Sana Biotechnology Inc's Net Income (Common) amounts to -283.3m USD.

What is Sana Biotechnology Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-84%

Over the last year, the Net Income (Common) growth was -5%.

Back to Top